ClinicalTrials.gg
Active, not recruitingNCT04578938Updated Mar 24, 2026

Ketamine + Cognitive Training for Suicidality in the Medical Setting

A Phase 4 interventional study of Intravenous ketamine and Cognitive training in Suicide, Attempted, sponsored by Rebecca Price. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Rebecca Price · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 149 studies in Suicide, Attempted with a site in United States — 53 open to participants now, 58 under way, 1 of them phase 3. Suicide, Attempted · United States.

Enrollment
46th of 140
200 · median 117
Started
2021
with 11 others
Phase 4
3 of 149
none open now
Primary completion
2026-12
later than 12 of 57 live
Registered
67th of 149
by date

Among the 149 studies in Suicide, Attempted with a site in United States, this one is the 46th largest by enrollment of the 140 interventional ones that give a count, is one of 12 that started in 2021, is one of 3 in phase 4, reaches primary completion later than 12 of the 57 other live ones, and was the 67th registered.

Suicide, Attempted

281 studies on the registry are indexed under Suicide, Attempted; 90 are open to participants now.

Browse Suicide, Attempted studies →

Open to participants now

53 of the 149 studies in Suicide, Attempted with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Suicide, Attempted studies recruiting now, 34 (51%) set no upper age limit and 32 (48%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Suicide, Attempted with a site in United States, or all of them as a file.
02

Study summary

This project seeks to identify the acute and longer-term impact of a single dose of intravenous ketamine among suicidal patients referred for psychiatric consultation/liaison in the medical inpatient setting. The investigators will then test whether ketamine's rapid effects can be extended by introducing helpful information delivered by a computer-based training protocol. This work could ultimately lead to the ability to treat suicidality more efficiently and with broader dissemination by rapidly priming the brain for helpful forms of learning.

Read the detailed description

NOTE: Edits were made to the outcome measures sections to improve clarity regarding the a priori analytic plan with respect to the "Time Frame" of measurements and to reduce redundancies. Timepoints that will be analyzed as trajectories over windows of time and measurements that will be analyzed as composites are now more clearly specified. The previous entries correctly identified all relevant measures and timepoints, but implied incorrectly that each timepoint/measure would be analyzed in isolation.

03/19/26: Edit to upper age limit made to correct a previous data entry error and align with IRB-approved protocol.

03

Conditions studied

  • Suicide, Attempted

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants who receive ketamine will:

  1. be between the ages of 18 and 70 years
  2. be a medical inpatient referred for psychiatric consultation/liaison due to suicidality and determined by psychiatric C/L to require follow-up psychiatric care (inpatient or outpatient)
  3. possess a level of judgment and understanding sufficient to agree to all procedures required by the protocol and must sign an document
  4. be deemed an appropriate and reasonable medical candidate for intravenous ketamine by a physician authorized to prescribe medication to the patient during inpatient hospitalization

Exclusion criteria

Exclusion Criteria:

  1. Presence of current/acute psychosis with significant thought disruption, mania, delirium, or dementia, or a diagnosis of developmental disorder with significant language and/or intellectual impairment
  2. (MMSE) \< 21
  3. Current pregnancy or breastfeeding
  4. Reading level \<5th grade as per WRAT-3 reading subtest AND patient declines to have all questionnaire items and task instructions read aloud to them at all assessment points
  5. Past intolerance or to ketamine or esketamine
  6. Patients taking St John's Wort
  7. Patients who have received ECT in the past 1 month prior to intake
  8. Patients at ongoing risk for severe substance or alcohol withdrawal related issues (e.g., delirium tremens, severe opiate withdrawal) or who present with substance-induced psychosis
  9. Arrested or incarcerated individuals brought in by the legal system for medical stabilization
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Ketamine + Cognitive Training

    Drug: Intravenous ketamine · Behavioral: Cognitive training

  • Sham comparator
    Ketamine + Sham Training

    Drug: Intravenous ketamine · Behavioral: Sham Training

  • Active comparator
    No-infusion (TAU) + Cognitive Training

    Behavioral: Cognitive training

  • Sham comparator
    No-infusion (TAU) + Sham Training

    Behavioral: Sham Training

Interventions

  • DrugKetamineStudies of KetamineKetamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Single subanesthetic infusion of ketamine (0.5mg/kg)

  • BehavioralCognitive training

    8 sessions of computer-based cognitive training

  • BehavioralSham Training

    8 sessions of computer-based sham training

06

What researchers measure

Primary outcomes

  1. Scale for Suicide Ideation

    suicidal ideation/thoughts; range 0-38; high score=worse outcome

    Time frame: Trajectories from 24hrs through 1 month

  2. Montgomery Asberg Depression Rating Scale

    depression severity; range 0-60; high score=worse outcome

    Time frame: Trajectories from 24hrs through 1 month

  3. Suicidal behaviors: medical chart review and Columbia Suicide Severity Rating Scale (CSSRS)

    composite measure of # unique occurrences of any suicidal outcome (recorded via either measure) including: re-attempt, re-hospitalization for suicidality, suicide behaviors, or completed suicide

    Time frame: Trajectories from 24hrs through 12 months

Secondary outcomes

  1. Adult Suicide Ideation Questionnaire

    suicidal ideation/thoughts; range 0-150; high score=worse outcome

    Time frame: Trajectories from 24hrs through 12 months

  2. Quick Inventory of Depressive Symptoms

    Self-reported depression (range: 0-27; higher scores = worse outcome)

    Time frame: Trajectories from 24hrs through 12 months

  3. Scale for Suicide Ideation

    suicidal ideation/thoughts; range 0-38; high score=worse outcome

    Time frame: Trajectories from 1 month through 12 months

  4. Montgomery Asberg Depression Rating Scale

    depression severity; range 0-60; high score=worse outcome

    Time frame: Trajectories from 1 month through 12 months

Other outcomes

  1. Implicit Association Test

    performance-based "target engagement" measure of suicidal cognition; range = -inf-inf; high score=worse outcome

    Time frame: Trajectories from 24hrs through 1 week

  2. Implicit Association Test

    performance-based "target engagement" measure of suicidal cognition; range = -inf-inf; high score=worse outcome

    Time frame: Trajectories from 1 week through 12 months

  3. Acceptability: infusion

    self-report slider scale rating; range = 0-100; high score=better rating

    Time frame: Post-CT assessment (approximately +5 days post-randomization)

  4. Satisfaction: infusion

    self-report slider scale rating; range = 0-100; high score=better rating

    Time frame: Post-CT assessment (approximately +5 days post-randomization)

  5. Future likelihood of use: infusion

    self-report slider scale rating; range = 0-100; high score=better rating

    Time frame: Post-CT assessment (approximately +5 days post-randomization)

  6. Ease of use: Cognitive Training

    self-report slider scale rating; range = 0-100; high score=better rating

    Time frame: Post-CT assessment (approximately +5 days post-randomization)

  7. Helpfulness: Cognitive Training

    self-report slider scale rating; range = 0-100; high score=better rating

    Time frame: Post-CT assessment (approximately +5 days post-randomization)

  8. Satisfaction: Cognitive Training

    self-report slider scale rating; range = 0-100; high score=better rating

    Time frame: Post-CT assessment (approximately +5 days post-randomization)

  9. Future likelihood of use: Cognitive Training

    self-report slider scale rating; range = 0-100; high score=better rating

    Time frame: Post-CT assessment (approximately +5 days post-randomization)

  10. PROMIS Pain Intensity score

    PROMIS Pain Intensity Short Form scale T-score (range=0-100; higher score=worse pain)

    Time frame: 24 hrs post-randomization

  11. PROMIS Pain Intensity score

    PROMIS Pain Intensity Short Form scale T-score (range=0-100; higher score=worse pain)

    Time frame: Post-CT assessment (approximately +5 days post-randomization)

  12. PROMIS Neuropathic Pain Quality

    PROMIS Neuropathic Pain Quality scale T-score (range=0-100; higher score=worse pain)

    Time frame: 24 hrs post-randomization

  13. PROMIS Neuropathic Pain Quality

    PROMIS Neuropathic Pain Quality scale T-score (range=0-100; higher score=worse pain)

    Time frame: Post-CT assessment (approximately +5 days post-randomization)

  14. PROMIS Nociceptive Pain Quality

    PROMIS Nociceptive Pain Quality scale T-score (range=0-100; higher score=worse pain)

    Time frame: 24 hrs post-randomization

  15. PROMIS Nociceptive Pain Quality

    PROMIS Nociceptive Pain Quality scale T-score (range=0-100; higher score=worse pain)

    Time frame: Post-CT assessment (approximately +5 days post-randomization)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2021 (actual). Primary completion is estimated for Dec 2026, 68 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2020
First posted
Oct 8, 2020
StartActual
Mar 15, 2021
Primary completionEst.
Dec 2, 2026
CompletionEst.
Dec 2, 2026
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04578938
Lead sponsor
Rebecca Price
Responsible party
Rebecca Price (Associate Professor of Psychiatry and Psychology, University of Pittsburgh) — Sponsor-investigator
First posted
Oct 8, 2020
Start date
Mar 15, 2021
Primary completion
Dec 2, 2026 (estimated)
Completion
Dec 2, 2026 (estimated)
Last update
Mar 24, 2026

Study contacts

Rebecca B Price, PhD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion